<i>ESR1</i> F404 Mutations and Acquired Resistance to Fulvestrant in <i>ESR1</i> -Mutant Breast Cancer
Belinda Kingston(Breast Cancer Now), Nicholas C. Turner(Royal Marsden NHS Foundation Trust)
Cited by 35
Related Papers
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
|Annals of Oncology|2022|633
A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
|Clinical Cancer Research|2010|323
Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
|Nature Communications|2020|258